621 completed, 210 terminated, 174 recruiting, 142 unknown. 1329 Phase 2, 364 Phase 1, 29 Phase 3.
Follow Ovarian Neoplasms: new trials by email Literature Review of Ovarian Neoplasms trials Research Report on Ovarian Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer losartan, Paclitaxel - Platinum Resistant Ovarian Cancer | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 27 | 2027-02-01 | 2026-09-22 |
| PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 130 | 2026-12-31 | 2026-11-17 |
| Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab Fludarabine, Cyclophosphamide - Ovarian Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 20 | 2026-12-01 | 2026-07-22 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial Imlunestrant, Abemaciclib, Selinexor - Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 60 | 2026-12-01 | 2026-09-21 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 558 | 2026-11-15 | 2026-11-12 |
| MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer Mirvetuximab Soravtansine, Suvemcitug - Platinum-Sensitive Recurrent Ovarian Cancer | Phase 2 | Not yet recruiting | Tongji Hospital | 80 | 2026-11-10 | 2026-11-12 |
| Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management Treatment De-escalation, Additional Treatment - Co-existent Endometrial and Ovarian Carcinoma, Ovarian Carcinoma | Phase 2 | Not yet recruiting | British Columbia Cancer Agency | 90 | 2026-10-30 | 2026-11-16 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors CR-002 - Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ | Phase 1 / Phase 2 | Recruiting | Crescent Biopharma, Inc. | 219 | 2026-10-21 | 2026-11-02 |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Carboplatin, Bevacizumab - Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 176 | 2026-09-30 | 2026-08-20 |
| A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. TJ102 - Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Phrontline Biopharma | 150 | 2026-09-29 | 2026-11-12 |
| Evaluation of XYA02 in Patients With Advanced Solid Tumors XYA02 - MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | XYone Therapeutics, Inc | 190 | 2026-09-17 | 2026-09-25 |
| IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 2 | Recruiting | University of Washington | 26 | 2026-09-16 | 2026-11-02 |
| Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer Sacituzumab tirumotecan, Pembrolizumab - Ovarian Clear Cell Carcinoma, Metastatic Ovarian Cancer | Phase 2 | Recruiting | Tufts Medical Center | 50 | 2026-09-12 | 2026-11-10 |
| A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of Chicago | 24 | 2026-09-09 | 2026-10-13 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | University of Colorado, Denver | 40 | 2026-09-01 | 2026-09-11 |
Showing 20 of 1329. Sign in to see all of them.
Fallopian Tube Neoplasms (365) · Carcinoma, Ovarian Epithelial (333) · Breast Neoplasms (160) · Endometrial Neoplasms (136) · Neoplasms (113) · Carcinoma, Non-Small-Cell Lung (100) · Uterine Cervical Neoplasms (100) · Colorectal Neoplasms (97) · Pancreatic Neoplasms (88) · Recurrence (76) · Stomach Neoplasms (76) · Sarcoma (72) · Melanoma (65) · Lung Neoplasms (58)
Urogenital Diseases (1329) · Female Urogenital Diseases (1328) · Female Urogenital Diseases and Pregnancy Complications (1328) · Genital Diseases (1328) · Gonadal Disorders (1327) · Adnexal Diseases (1325) · Endocrine System Diseases (1325) · Genital Diseases, Female (1322) · Urogenital Neoplasms (1319) · Endocrine Gland Neoplasms (1318) · Genital Neoplasms, Female (1316) · Neoplasms by Site (1316) · Ovarian Diseases (1314) · Neoplasms (1216) · Neoplasms by Histologic Type (553)
Carboplatin (202) · Paclitaxel (191) · Bevacizumab (120) · pembrolizumab (72) · Gemcitabine (66) · Cyclophosphamide (56) · liposomal doxorubicin (51) · Cisplatin (50) · olaparib (49) · Topotecan (47) · Docetaxel (37) · niraparib (33) · Nivolumab (29) · Taxes (28) · Filgrastim (27)
National Cancer Institute (NCI) (96) · Gynecologic Oncology Group (36) · Memorial Sloan Kettering Cancer Center (30) · M.D. Anderson Cancer Center (27) · Eli Lilly and Company (19) · AstraZeneca (17) · Dana-Farber Cancer Institute (15) · ARCAGY/ GINECO GROUP (14) · Masonic Cancer Center, University of Minnesota (11) · Mayo Clinic (11) · Fred Hutchinson Cancer Center (10) · Roswell Park Cancer Institute (10) · European Organisation for Research and Treatment of Cancer - EORTC (9) · AGO Study Group (8) · Cancer Research UK (8)
United States (789) · China (151) · Canada (135) · United Kingdom (122) · Spain (121) · France (98) · Belgium (87) · Italy (85) · Germany (81) · Australia (76) · South Korea (65) · Netherlands (46) · Israel (38) · Japan (37) · Denmark (35)
Amir A Jazaeri (5) · Amit Oza (5) · Emese Zsiros (5) · Paul Sabbatini, MD (5) · Steven A Rosenberg, M.D. (5) · Ursula Matulonis, MD (5) · Amy D. Tiersten, MD (4)
PMID 37185961, PMID 35170751, PMID 37407274, PMID 19238149, PMID 23922302, PMID 26961146, PMID 35537408, PMID 41044356, PMID 28935273, PMID 31685558, PMID 33337539, PMID 35397664, PMID 36718018, PMID 37496366, PMID 38816232, PMID 39123210, PMID 39695768, PMID 11705489, PMID 11919245, PMID 12065559, PMID 12181243, PMID 12528778, PMID 12586591, PMID 12694666, PMID 12713990, PMID 12826431, PMID 12957454, PMID 14534883, PMID 14615449, PMID 14645425, PMID 14701774, PMID 14767498, PMID 14970858, PMID 15010069, PMID 15177491, PMID 15581974, PMID 15589582, PMID 15592836, PMID 15659504, PMID 15661234, PMID 15699482, PMID 15721430, PMID 15864277, PMID 15999362, PMID 16014111, PMID 16061871, PMID 16249022, PMID 16314647, PMID 16325893, PMID 16500907
U10CA027469 (34), U10CA180868 (27), 2023 (19), 2008 (10), 2009 (10), 2016 (9), 2025 (8), P30CA008748 (8), 2015 (7), 2017 (7), N01CM62203 (7), P30CA015083 (6), 2018 (5), N01CM62201 (5), N01CM62209 (5)